MedTrace Logo

Acute Dose Response of Korean White Ginseng in Metabolic Syndrome or Type 2 Diabetes

NCT01699074 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-04-15

No results posted yet for this study

Summary

The study is a Phase-I like double blind randomized placebo controlled crossover design trial. The objective is to assess the dose response relationship on glycemic and vascular effects of an acutely administered Korean White Ginseng (KWG)(Panax C.A. Meyer) in individuals with metabolic syndrome or type 2 diabetes . Twenty seven subjects with Type 2 Diabetes (Key inclusion criteria: HbA1c ≤8.5%)or metabolic syndrome (Key inclusion criteria: as defined by The US National Cholesterol Education Program Adult Treatment Panel III)will be recruited for the study.

Conditions

Interventions

DIETARY_SUPPLEMENT

1 gram of White Korean Ginseng

1 gram of White Korean Ginseng

DIETARY_SUPPLEMENT

3 grams of White Korean Ginseng

3 grams of White Korean Ginseng

DIETARY_SUPPLEMENT

6 grams of White Korean Ginseng

6 grams of White Korean Ginseng

DIETARY_SUPPLEMENT

3 grams of Wheat Bran Control

3 grams of Wheat Bran Control

DIETARY_SUPPLEMENT

500mg of Korean Red Ginseng

500mg of Korean Red Ginseng

Sponsors & Collaborators

  • Unity Health Toronto

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2013-09-30
Completion
2014-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01699074 on ClinicalTrials.gov